Description

Retatrutide works by activating multiple metabolic pathways involved in appetite regulation, energy expenditure, and glucose control. By stimulating GLP-1 and GIP receptors, it helps reduce appetite, slow gastric emptying, and improve insulin sensitivity, while activation of the glucagon receptor may increase energy expenditure and fat metabolism.

Early clinical research has shown significant reductions in body weight and body fat, making retatrutide one of the most promising next-generation therapies being studied for obesity and metabolic disease. Because it targets three metabolic pathways simultaneously, it is often described as a “triple agonist” weight-management peptide with potentially greater effects than earlier GLP-1–based treatments.